191
Conclusions
•
Asthma remains a global epidemic
•
A significant number of cases are not
controlled with maximal drug treatment
–
More options are needed
•
Omalizumab, the first biological against severe
allergic asthma, is an important breakthrough
Omalizumab was well tolerated
•
The majority of serious AEs were asthma‐related hospitalizations
•
Seven patients had anaphylaxis: six in the placebo group and one in the omalizumab group
–
the patient in the omalizumab group had a mild cough and throat pruritus after receiving the final omalizumab
injection during the study
AE = adverse event.
Busse WW,
et al. N Engl J Med
2011;364:1005–15.
One or more AEs
One or more serious AEs
Omalizumab
Placebo
13.7%
ICATA
6.3%
39.4%
47.4%
Simposium
